EQS-News

Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022

EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022 10.11.2022 / 15:24 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE

Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022

• Heidelberg Pharma presents initial findings of the first in human study with ATAC candidate HDP-101
• Licensing partner Magenta presents initial data from Phase I/II study with ATAC candidate MGTA-117

Ladenburg, Germany, 10 November 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it will present initial data from the Phase I/IIa clinical trial with HDP-101 at the 64^th Annual Meeting of the American Society of Hematology (ASH). In addition, partner Magenta Therapeutics, Cambridge, MA, USA, (Magenta) (NASDAQ: MGTA) will present data from its clinical trial with MGTA-117. The conference will take place from December 10 to 13, 2022 in New Orleans, USA.

Dr. András Strassz, Chief Medical Officer of Heidelberg Pharma AG, commented: "We are excited to present initial safety data of the first in human study with HDP-101, an Antibody Drug Conjugate with the highly potent payload Amanitin, at the ASH meeting. Up to now, HDP‑101 has shown good tolerability in late stage relapsed and/or refractory multiple myeloma patients. The study is currently enrolling patients in the third cohort and we are curious to see further safety and efficacy data.”

Poster title: HDP-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

Presentation details

Abstract #3219

Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II

Time and location: Sunday, December 11, 2022, 6:00pm - 8:00pm CST, Hall D (Ernest N. Morial Convention Center)

Dr. Strassz will present the poster showing initial clinical data of the ongoing open-label, multi-center Phase I/IIa trial evaluating HDP-101 in multiple myeloma. He will also be available to answer questions.